Skeletal tumor burden on baseline 18F-fluoride PET/CT predicts bone marrow failure after 223Ra therapy

Clinical Nuclear Medicine

Volumn 41, Issue 4, 2016, Pages 268-273

  Etchebehere, Elba C ^a,b   Araujo, John C ^c   Milton, Denái R ^c   Erwin, William D ^a   Wendt, Richard E ^a   Swanston, Nancy M ^a   Fox, Patricia ^c   Macapinlac, Homer A ^a   Rohren, Eric M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c Department of Genitourinary Medical Oncology ^*  (United States)

Author keywords

223Ra; Bone marrow failure; Bone metastases; Fluoride PET CT; Prostate cancer; Skeletal tumor burden

Indexed keywords

ABIRATERONE; CABAZITAXEL; CARBOPLATIN; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; DOCETAXEL; ENZALUTAMIDE; FLUORODEOXYGLUCOSE F 18; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; RADIUM CHLORIDE RA 223; SODIUM FLUORIDE F 18; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RADIUM;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW DEPRESSION; BONE METASTASIS; BONE PAIN; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTOPENIA; ADVERSE EFFECTS; BONE MARROW; BONE NEOPLASMS; DIAGNOSTIC IMAGING; EVALUATION STUDY; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY; PROSTATIC NEOPLASMS; RADIATION RESPONSE; SECONDARY; TUMOR VOLUME; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

AGED; AGED, 80 AND OVER; BONE MARROW; BONE NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY; RADIUM; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84961405267     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000001118     Document Type: Article

References (25)

1. Khafagy R, Shackley D, Samuel J, et al. Complications arising in the final year of life in men dying from advanced prostate cancer. J Palliat Med. 2007;10:705-711.
2. Nalesnik JG, Mysliwiec AG, Canby-Hagino E. Anemia in men with advanced prostate cancer: incidence, etiology, and treatment. Rev Urol. 2004; 6:1-4.
3. Strum SB, McDermed JE, Scholz MC, et al. Anaemia associated with andro-gen deprivationin patients with prostate cancer receiving combined hormone blockade. Br J Urol. 1997;79:933-941.
4. Nieder C, Haukland E, Pawinski A, et al. Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases. BMC Cancer. 2010; 10:284.
5. Tu SM, Kim J, Pagliaro LC, et al. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol. 2005;23:7904-7910.
6. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213-223.
7. Kluetz PG, Pierce W, Maher VE, et al. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2014;20:9-14.
8. Joung JY, Ha YS, Kim IY. Radium Ra 223 dichloride in castration-resistant prostate cancer. Drugs Today (Barc). 2013;49:483-490.
9. Etchebehere EC, Pereira Neto CA, Lima MC, et al. Treatment of bone pain secondary to metastases using samarium-153-EDTMP. Sao Paulo Med J. 2004;122:208-212.
10. Tolia M, Zygogianni A, Kouvaris JR, et al. The key role of bisphosphonates in the supportive care of cancer patients. Anticancer Res. 2014;34:23-37.
11. Basch E, Autio K, Ryan CJ, et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 2013;14:1193-1199.
12. 18F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scin-tigraphy. Eur J Nucl Med Mol Imaging. 2012;39:1730-1736.
13. Etchebehere E, Araujo JC, Fox PS, et al. Prognostic factors in patients treated with 223Ra: the role of skeletal tumor burden on baseline 18F-fluoride PET/CT in predicting overall survival. J Nucl Med. 2015;56: 1177-1184.
14. 18F-fluoride PET/CT. J Nucl Med. 2015;56:1454.
15. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonpara-metric approach. Biometrics. 1988;44:837-845.
16. Geenen RW, Delaere KP, van Wersch JW. Haematological variables in pros-tatic carcinoma patients. Acta Urol Belg. 1996;64:21-26.
17. Ebbe S, Phalen E, Threatte G, et al. Modulation of radiation-induced hemo-poietic suppression by acute thrombocytopenia. Ann N Y Acad Sci. 1985; 459:179-189.
18. Salacz ME, Lankiewicz MW, Weissman DE. Management of thrombocyto-penia in bone marrow failure: a review. J Palliat Med. 2007;10:236-244.
19. Fizazi K, Massard C, Smith M, et al. Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer. Eur Urol. 2015;68:42-50.
20. Lassmann M, Nosske D. Dosimetry of 223Ra-chloride: dose to normal organs and tissues. Eur J Nucl Med Mol Imaging. 2013;40:207-212.
21. Madani I, De Neve W, Mareel M. Does ionizing radiation stimulate cancer invasion and metastasis? Bull Cancer. 2008;95:292-300.
22. Sun R, Sbai A, Ganem G, et al. Non-targeted effects (bystander, abscopal) of external beam radiation therapy: an overview for the clinician [in French]. Cancer Radiother. 2014;18:770-778.
23. Park B, Yee C, Lee KM. The effect of radiation on the immune response to cancers. Int J Mol Sci. 2014;15:927-943.
24. Wegiel B, Evans S, Hellsten R, et al. Molecular pathways in the progression of hormone-independent and metastatic prostate cancer. Curr Cancer Drug Targets. 2010;10:392-401.
25. Rüegg C, Monnier Y, Kuonen F, et al. Radiation-induced modifications of the tumor microenvironment promote metastasis. Bull Cancer. 2011;98: 47-57.